Physician profile
Chester Cedars
NPI 1740397090
$1,067.77
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $29.30 · 2021: $124 · 2022: $13.34.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $297.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $228.05 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $175.07 | 2019 | |
| Novo Nordisk INC | $153.71 | 2019 | |
| Allergan, INC. | $51.95 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $47.62 | 2019-2020 | |
| Gilead Sciences, INC. | $22.49 | 2019 | |
| Radius Health, INC. | $19.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.49 | 2020 | |
| Amarin Pharma, INC. | $15.11 | 2019 | |
| Nevro Corp. | $13.34 | 2022 | |
| Antares Pharma, INC. | $13.18 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chester Cedars listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.